

The invention enables to provide vaccines which raise an efficient immunologic response. As a consequence, the design of better prophylactic and therapeutic vaccines against HCMV but also for gene therapy approaches can be presented.
Further Information: PDF
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Phone: +49 (0)89/1205-6000
Contact
Dr. Wolfgang Knappe